

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 6, 2013

Date of Report (Date of earliest event reported)

TAPIMMUNE INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

000-27239

(Commission File Number)

88-0277072

(IRS Employer Identification No.)

1551 Eastlake Avenue East, Suite 100, Seattle,

WA

(Address of principal executive offices)

98102

(Zip Code)

(206) 504-7278

Registrant's telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of February 6, 2013, James W. Fuller has resigned from his position as a director of our company. This resignation did not result from any dispute or disagreement with us, our independent accountants, our counsel or our operations, policies and practices.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 (d)Exhibits.

Exhibit Exhibit Description

99.1 Letter of Resignation from James Fuller, dated February 6, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TAPIMMUNE INC.

Date: February 20, 2013

By: /s/ Glynn Wilson
Name: Glynn Wilson
Title: Chairman and CEO

February 5, 2013

To TapImmune Inc.:

This will serve as my resignation, effective February 6, 2013, from the Board of Directors of TapImmune Inc. ("TapImmune"). This resignation does not arise from, or is the result of, any disagreements with TapImmune, TapImmune's independent accountants, TapImmune's counsel or with TapImmune's operations, policies or practices.

I have read the draft of TapImmune's Current Report on Form 8-K describing my resignation and agree with the statements made by TapImmune regarding my resignation.

Sincerely,

/s/James Fuller

James Fuller
